Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

2.

Increases in aggregation by and uptake of 5-hydroxytryptamine with platelets from rabbits treated with chlorpromazine.

Baldacci M, Baldacci M, Bergel TD, Born GV, Hickman M.

Br J Pharmacol. 1980 May;69(1):113-8.

3.
4.

The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients.

Orr MW, Knox JM, Allen R, Gelder MG, Grahame-Smith DG.

Br J Clin Pharmacol. 1981 Mar;11(3):255-9.

5.

Assessment of anti-psychotic drugs.

Mackay AV.

Br J Clin Pharmacol. 1981 Mar;11(3):225-36. Review. No abstract available.

6.

Platelet function defects in chronic alcoholism.

Jones EW.

Br Med J (Clin Res Ed). 1986 Nov 15;293(6557):1307. No abstract available.

7.

Increased platelet membrane [3H]-LSD binding in patients on chronic neuroleptic treatment.

Sch├Ąchter M, Geaney DP, Grahame-Smith DG, Cowen PJ, Elliott JM.

Br J Clin Pharmacol. 1985 Apr;19(4):453-7.

8.
11.

Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response.

Aronson JK, Grahame-Smith DG, Hallis KF, Hibble A, Wigley F.

Br J Clin Pharmacol. 1977 Apr;4(2):213-21.

12.
13.

Platelet aggregation and chlorpromazine therapy.

Boullin DJ, Know JM, Peters JR, Orr MW, Gelder MG, Grahame-Smith DG.

Br J Clin Pharmacol. 1978 Dec;6(6):538-40. No abstract available.

Supplemental Content

Support Center